Finch’s microbiome therapy clears bar in pivotal C. diff readout

A pivotal Phase II readout for Finch’s microbiome treatment for recurrent Clostridium difficile infection paves the way for a Phase III trial that will further test the therapy in a broad population for which the company is seeking its approval.

Finch Therapeutics Group Inc. said Friday’s results represent the first time an oral microbiome therapy has ever met the primary endpoint in a pivotal clinical trial. “This shows for the first time that an oral microbiome drug works and can improve clinically important outcomes for patients,” CEO Mark Smith told BioCentury...